SymBio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
SymBio Pharmaceuticals has a total shareholder equity of ¥5.2B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥6.1B and ¥910.3M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥5.13b |
| Equity | JP¥5.16b |
| Total liabilities | JP¥910.31m |
| Total assets | JP¥6.07b |
Recent financial health updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24
Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09Recent updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge
Jun 11Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%
Dec 18Financial Position Analysis
Short Term Liabilities: 4582's short term assets (¥6.0B) exceed its short term liabilities (¥906.0M).
Long Term Liabilities: 4582's short term assets (¥6.0B) exceed its long term liabilities (¥4.3M).
Debt to Equity History and Analysis
Debt Level: 4582 is debt free.
Reducing Debt: 4582 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4582 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4582 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 34.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 02:00 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SymBio Pharmaceuticals Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathaniel Calloway | Edison Investment Research |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |